Schizophrenia, antipsychotics and metabolic disease

Journal of Psychopharmacology

Volumn 21, Issue 4, 2007, Pages 355-356

  Reynolds, Gavin P ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; ZIPRASIDONE;

CLINICAL FEATURE; DIABETOGENESIS; EDITORIAL; GLUCOSE METABOLISM; HUMAN; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LIFE EXPECTANCY; LIFESTYLE; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERLIPIDEMIAS; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 34447534307     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107080215     Document Type: Editorial

References (4)

1. Bjorntorp P. (2001) Heart and soul: stress and the metabolic syndrome. Scand Cardiovasc J 35: 172 - 177
2. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., Selke G. (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiat 59: 337 - 345
3. Wannamethee S.G., Shaper A.G., Perry I.J. (2001) Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men. Diab Care 24: 1590 - 1595
4. Zhang Z.J., Yao Z.J., Liu W., Fang Q., Reynolds G.P. (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Brit J Psychiat 184: 58 - 62